Outcomes of autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease: a single-center retrospective case series
Acta Gastro-Enterologica Belgica · 2026-06 · 89 (2) · 325-332
DOI: 10.51821/89.2.15503 ↗At a glance
Journal article in Acta Gastro-Enterologica Belgica, 2026-06. Written by G Geebelen and 8 co-authors. Institution: University Hospitals Leuven, Department of Gasteroenterology and Hepatology, B-3000 Leuven, Belgium. Major MEDLINE topics: Crohn Disease, Hematopoietic Stem Cell Transplantation.
Abstract (original language)
Background and aims Despite advances in biological therapies, a subset of patients with Crohn’s disease (CD) remains or becomes refractory to all available treatments. Emerging evidence indicates that autologous hematopoietic stem cell transplantation (aHSCT) may offer a viable therapeutic option for carefully selected treatment-refractory CD patients. Patients and methods We retrospectively analyzed the outcomes of all CD patients who underwent aHSCT for treatment-refractory disease at our IBD referral center between 2011 and 2023. All included patients had severe disease, unsuitable for surgery.
Results
We included 24 CD patients (15 females, median age at transplantation 31.0 [27.0-34.5] years, median disease duration 13.0 [9.8-17.3] years) who underwent mobilization, of whom 23 patients proceeded to transplantation. All patients had CD with small bowel involvement, while 10 patients (41.7%) had concomitant perianal disease. After a median follow-up of 114.6 [66.0-138.4] months, 8 patients (34.8%) were still in remission without need for advanced therapy. Persistent disease activity after aHSCT, defined as total SES-CD >3, occurred in 15 patients (65.2%) with median time to restarting advanced therapy of 7.0 [5.0-25.0] months. At last follow-up, all patients are still alive. There were a few ICU admissions because of hemodynamic instability due to neutropenic fever following mobilization and transplantation. In the follow-up period, infectious complications occurred in 12 patients (52.2%).
Conclusions
Autologous hematopoietic stem cell transplantation is a safe and effective therapy for inducing and maintaining remission in carefully selected therapy-refractory CD patients after extensive multidisciplinary discussion. Although many patients didn’t achieve remission, most regained response to previously ineffective therapies
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- University Hospitals Leuven, Department of Gasteroenterology and Hepatology, B-3000 Leuven, Belgium.
- University Hospitals Leuven, Department of Hematology, B-3000 Leuven, Belgium.
- KU Leuven, Department of Chronic Diseases and Metabolism, B-3000 Leuven, Belgium.
- KU Leuven, Department of Oncology, B-3000 Leuven, Belgium.
Cite
APA
Geebelen, G., Van Besien, A., Van Ham, J., D'Hooghe, A. T., Ferrante, M., Sabino, J., Verstockt, B., Dierickx, D., & Vermeire, S. (2026). Outcomes of autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease: a single-center retrospective case series. Acta Gastro-Enterologica Belgica, 89(2), 325-332. https://doi.org/10.51821/89.2.15503
Vancouver
Geebelen G, Van Besien A, Van Ham J, D'Hooghe AT, Ferrante M, Sabino J, et al. Outcomes of autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease: a single-center retrospective case series. Acta Gastro-Enterologica Belgica. 2026;89(2):325-332. doi:10.51821/89.2.15503
BibTeX
@article{Geebelen2026,
author = {Geebelen, G and Van Besien, A and Van Ham, J and D'Hooghe, A T and Ferrante, M and Sabino, J and Verstockt, B and Dierickx, D and Vermeire, S},
title = {Outcomes of autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease: a single-center retrospective case series},
journal = {Acta Gastro-Enterologica Belgica},
year = {2026},
volume = {89},
number = {2},
pages = {325--332},
doi = {10.51821/89.2.15503}
}
EUVIMED